The U.S. Food and Drug Administration (FDA) approved a second generic version of the abortion pill mifepristone on October 2, 2025, just hours before a potential government shutdown that would have paused regulatory functions. The decision allows Evita Solutions to manufacture and market a 200 mg generic formulation of the drug, joining GenBioPro as the only other company with FDA authorization to produce a generic equivalent.
Mifepristone is one of two medications used in the most common regimen for medication abortions in the United States, typically administered within the first 10 weeks of pregnancy. It is followed by misoprostol to complete the process. The pill was originally approved in 2000 and has remained under continued scrutiny due to its role in reproductive healthcare and ongoing legal and political debates.
The FDA granted the new approval through its abbreviated new drug application (ANDA) process, which evaluates whether a proposed generic is bioequivalent to an already approved drug. Federal law mandates that the FDA approve such applications when equivalency is demonstrated, without reassessing the broader public policy implications. Evita Solutions filed its ANDA in October 2021.
The approval came amid heightened political attention to abortion access in the United States, particularly surrounding medication abortion. In April, a controversial study alleging increased risks associated with mifepristone prompted calls from some lawmakers for further regulatory review. Health and Human Services Secretary Robert F. Kennedy Jr. had announced an intent to conduct a scientific reassessment of the drug, but the FDA’s generic drug division continued its review of Evita’s application under standard procedures.
Approval follows rising national scrutiny of abortion drugs
While the approval does not alter the drug’s current usage guidelines or federal regulations governing its distribution, it may introduce increased market competition and potentially lower costs. However, access remains limited in several states where restrictive abortion laws prohibit or tightly regulate the use of medication abortion, regardless of federal approvals. The decision triggered immediate reactions from lawmakers and advocacy groups across the political spectrum.
Opponents of abortion criticized the timing and questioned the regulatory process, while reproductive rights organizations welcomed the move as a validation of the drug’s longstanding safety profile. The FDA has stated repeatedly that mifepristone has been extensively studied and used safely by millions of patients globally for over two decades. GenBioPro, which received FDA approval for its generic version of mifepristone in 2019, is currently involved in litigation against several states seeking to restrict access to the drug.
Reactions reflect polarized national debate on abortion
The company has argued that state-level bans conflict with federal regulatory authority. The entrance of a second generic manufacturer could affect those legal dynamics, although the extent of market distribution will depend on pharmacy networks, provider availability, and ongoing court decisions. The FDA’s approval also came against the backdrop of a looming federal government shutdown, which would have suspended many regulatory functions had Congress failed to pass a continuing resolution.
The agency’s decision to finalize the approval before the deadline ensured that the generic product could proceed to market without administrative delay. Mifepristone remains a central component of abortion care in the United States, accounting for more than half of all abortion procedures nationwide. The introduction of an additional FDA-approved generic version marks a significant development in the landscape of reproductive healthcare regulation, even as broader legal and political battles over abortion access continue across multiple jurisdictions. – By Content Syndication Services.